Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Carcinoma, Small Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

atezolizumab 3Etoposide 2Cisplatin 2veliparib 1tivozanib 1surufatinib 1repotrectinib 1pralsetinib 1pembrolizumab 1durvalumab 1berzosertib 1avelumab 1Topotecan 1Podophyllotoxin 1Platinum 1Paclitaxel 1Nivolumab 1Ipilimumab 1Everolimus 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Neuroendocrine × Podophyllotoxin × Clear all
NCT01642251 2023-05-06

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 13 charts
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡